---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-049856"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2022-04-26T23:59:59+00:00"
generated_at: "2026-06-26T04:34:48.736978+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PN-943 Phase 2 IDEAL study shows 27.5% clinical remission at 150mg BID; 13% delta vs placebo

## Summary
- PN-943 150mg BID achieved 27.5% clinical remission vs 14.5% placebo (delta 13%, p=0.08); bio-naïve delta 16% (p=0.04).
- Statistically significant histological remission (RHI≤6) at 37.2% vs 14.3% placebo (delta 23%, p=0.0107).
- Endoscopic improvement: 43.1% vs 16.4% placebo (delta 26.7%, p=0.0023).
- 450mg BID showed no efficacy, consistent with bell-shaped dose-response observed for other α4β7 integrin antagonists.
- No drug-related SAEs; safety profile similar to placebo; company plans to advance to Phase 3 registrational study.

## SEC filing metadata
- accession: 0001104659-22-049856
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2022-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465922049856/0001104659-22-049856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465922049856/tm2213399d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-049856
- JSON: https://secwatch.observer/filing/0001104659-22-049856.json
- Plain text: https://secwatch.observer/filing/0001104659-22-049856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.